stars 1 stars 2 stars 3

Sol-Gel Technologies (NASDAQ: SLGL) is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our unique technology platform was designed to enable drug substances to be entrapped in porous silica microcapsules in order to address the limitations of topical drug delivery by stabilizing active drug ingredients, extending drug delivery time and reducing potential irritation caused by direct application to the skin. For more information, please visit www.Sol-Gel.com

Sol-Gel Technologies Questions

The Sol-Gel Technologies annual revenue was $129000 in 2026.

Itzik Yosef is the COO of Sol-Gel Technologies.

28 people are employed at Sol-Gel Technologies.

Sol-Gel Technologies is based in Ness Ziona, Central District.

The NAICS codes for Sol-Gel Technologies are [54, 541, 5417, 54171, 541712].

The SIC codes for Sol-Gel Technologies are [873, 87].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users